title: Doxycycline for the treatment of cutaneous leishmaniasis.
abstract: The incidence of cutaneous leishmaniasis has shown a resurgence in recent years in Tunisia. Because of the toxicity and high cost of pentavalent antimonials we have sought alternative medications. In a study of 14 patients with cutaneous leishmaniasis, ten patients achieved complete clinical regression of the lesions with oral administration of doxycycline, 200mg per day, for 15-30 days.
authors.forename: A
authors.initials: A
authors.lastname: Masmoudi
authors.forename: A
authors.initials: A
authors.lastname: Dammak
authors.forename: H
authors.initials: H
authors.lastname: Chaaben
authors.forename: N
authors.initials: N
authors.lastname: Maalej
authors.forename: F
authors.initials: F
authors.lastname: Akrout
authors.forename: H
authors.initials: H
authors.lastname: Turki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004318:Doxycycline / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D004318:Doxycycline